etoposide IV / Generic mfg. - LARVOL DELTA

SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=50 | Recruiting | Sponsor: AbbVie | N=27 ➔ 50

Adverse events • Enrollment change • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=180 | Recruiting | Sponsor: AbbVie | N=27 ➔ 180

Adverse events • Enrollment change • Trial initiation date • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

SEZanne: A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov) - P2 | N=27 | Recruiting | Sponsor: AbbVie

Adverse events • New P2 trial • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Anlotinib + Toripalimab maintenance in Extensive-Stage small cell lung Cancer: Clinical efficacy and preclinical mechanism of anlotinib-induced neuroendocrine differentiation Suppression via Notch1. (PubMed, Lung Cancer) - P2 | "Toripalimab plus anlotinib is associates with promising efficacy and acceptable safety as maintenance therapy in ES-SCLC. The therapeutic effect may be mediated through coordinated immunomodulation and anlotinib-induced changes in differentiation-related pathway, providing a mechanistic rationale for the observed clinical benefits. These results warrant further validation in randomized controlled trials."

IO biomarker • Journal • Preclinical • Immunology • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • GRP-10 • NOTCH1

Congenital mesoblastic nephroma: a single-center retrospective study. (PubMed, Transl Pediatr) - "Two relapsed patients received salvage chemotherapy [vincristine-actinomycin D-cyclophosphamide (VAC) or ifosfamide-carboplatin-etoposide (ICE)], which showed limited efficacy. One relapsed patient with TPM3::NTRK1 received larotrectinib but died two months later; another with EGFR-KDD experienced disease stabilization after afatinib plus programmed cell death protein 1 (PD-1) blockade following progression on entrectinib and anlotinib...While most patients experienced favorable outcomes following surgery, relapsed cases highlight the challenges associated with molecularly atypical disease. These observations are descriptive in nature and underscore the need for larger collaborative studies to better define prognostic factors and optimal management strategies in CMN."

IO biomarker • Journal • Retrospective data • Kidney Cancer • Oncology • Pediatrics • Renal Cell Carcinoma • Solid Tumor • EGFR • ETV6 • NTRK1 • NTRK3 • TPM3

Primary pure small cell neuroendocrine carcinoma of the endometrium: a case report. (PubMed, J Med Case Rep) - "Primary pure small cell neuroendocrine carcinoma of the endometrium is an exceptionally rare and highly malignant neoplasm associated with an unfavorable prognosis. Accurate diagnosis relies on histopathological and immunohistochemical evaluation. In this single-case observation, comprehensive surgical staging followed by platinum-based chemotherapy was administered. However, owing to the limited follow-up duration and the absence of adjuvant radiotherapy, definitive conclusions regarding treatment efficacy cannot be drawn. Larger case series and longer-term follow-up are required to establish optimal management strategies for this rare tumor."

Journal • Endocrine Cancer • Endometrial Cancer • Gastrointestinal Disorder • Gynecologic Neuroendocrine Carcinoma • Gynecology • Neuroendocrine Carcinoma • Obstetrics • Oncology • Solid Tumor

SPECTRUM OF KIDNEY INJURY ON RENAL BIOPSY FOLLOWING ANTICANCER DRUG TREATMENT (ISN-WCN 2026) - "Anticancer drugs used were TKI (Levatinib), Vincristine, cyclophosphamide, doxorubicin, etoposide; Paclitaxel Based Chemotherapy; Cyclophosphamide, Paclitaxel and Etoposide; and Capecitabine. On post renal biopsy follow-up of 1 month to 20 months, two patients succumbed; and two lost to follow-up.Conclusion Following anticancer drug treatment variety of lesions may be found affecting all renal compartments. Prompt diagnosis and treatment may prolong renal and patient survival."

Biopsy • Breast Cancer • Focal Segmental Glomerulosclerosis • Glomerulonephritis • IgA Nephropathy • Lupus Nephritis • Nephrology • Oncology • Ovarian Cancer • Renal Disease • Solid Tumor • Thyroid Gland Carcinoma • Thyroid Gland Follicular Carcinoma

BMAL1 silencing as a promising chemosensitizing strategy for triple-negative breast cancer. (PubMed, Acta Pharmacol Sin) - "This synergistically increases the sensitivity of TNBC cells to etoposide. Our findings reveal BMAL1 as a promising therapeutic target and support the potential of silencing BMAL1 with siRNA as a neoadjuvant strategy in combination with chemotherapeutic agents for the treatment of TNBC."

Journal • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • ARNTL • BMAL1 • CHEK1

Natural Killer/T-Cell Lymphoma-Associated Hemophagocytic lymphohistiocytosis-a Rare and Dangerous Disease. (PubMed, Blood Lymphat Cancer) - "The treatment of NK/T-LAHLH is still mainly based on chemotherapy regimens containing etoposide and dexamethasone. Recently, many new therapeutic drugs and schemes have been trialled for the treatment of NK/T-LAHLH, such as ruxolitinib, immune checkpoint inhibitors, pegaspargase, and the DEP regimen...Improving overall understanding of NK/T-LAHLH is of great significance to ameliorating patient prognosis. This review systematically discussed the epidemiology, pathogenesis, clinical features, current treatment regimens, and prognosis of NK/T-LAHLH to comprehensively elucidate this disease."

Journal • Review • Hematological Malignancies • Hemophagocytic lymphohistiocytosis • Immunology • Lymphoma • Natural Killer/T-cell Lymphoma • Oncology • Rare Diseases • T Cell Non-Hodgkin Lymphoma

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial. (PubMed, Lancet) - P3 | "BrECADD guided by PET after two cycles is better tolerated and more effective than eBEACOPP in first-line treatment of adult patients with advanced-stage, classical Hodgkin lymphoma."

Journal • Metastases • P3 data • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma • Oncology

Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study. (PubMed, Lancet Oncol) - P1, P3 | "Tarlatamab plus a PD-L1 inhibitor as maintenance after first-line chemo-immunotherapy showed a manageable safety profile with promising anticancer activity, supporting the ongoing phase 3 trial (NCT06211036)."

Journal • P1 data • Hematological Disorders • Infectious Disease • Lung Cancer • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • Small Cell Lung Cancer • Solid Tumor • DLL3

DAREON®-8: A phase I trial of first-line obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma (ES-SCLC) (ESMO 2025) - P1 | "We report the first safety and efficacy data for the dose escalation part of the Phase I DAREON®-8 (NCT06077500) trial investigating obrixtamig + first-line (1L) SoC (carboplatin + etoposide + atezolizumab) in patients (pts) with ES-SCLC. The frequency and severity of AEs reported for the combination were consistent with the expected safety findings of the individual treatments. The combinability of obrixtamig with chemotherapy and an anti-PDL1 antibody observed in this trial warrant further development of this combination in 1L ES-SCLC."

Clinical • P1 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • DLL3

Comprehensive Patient Reported Outcomes (PROs) from NRG LU005: A Randomized Trial Of Chemoradiation (CRT) +/- Atezolizumab In Limited-Stage Small Cell Lung Cancer (LS-SCLC) (ASTRO 2025) - "Materials/ Patients (N=544) were randomized to standard CRT (platinum/etoposide q3 weeks x 4 cycles + thoracic RT [45 Gy BID or 66 Gy daily] starting @ cycle 2 of chemo) +/- atezolizumab q3 weeks x 1 year starting @ cycle 2 of chemo. Stratification factors (SFs) included RT schedule (BID vs daily), chemo type (cisplatin vs carboplatin), sex, and ECOG performance status (PS)... As hypothesized, the addition of atezolizumab to CRT was associated with clinically meaningful improvements in longer term QOL (FACT-TOI), as well similar QAS with no negative impact on fatigue. To our knowledge, this is the first large trial to show that BID (vs daily) RT was associated with not only improved median OS, but also consistently more favorable PRO trajectory with significantly lower CMD in FACT-TOI. Conducted in the context of modern RT (IMRT ~90%), this analysis helps to address lingering concerns about BID RT's impact on QOL and provides further support for BID RT in LS-SCLC..."

Clinical • Late-breaking abstract • Patient reported outcomes • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

ZG005 in combination with etoposide and cisplatin for the first-line treatment of advanced neuroendocrine carcinoma (ESMO 2025) - P1/2 | "Background Advanced neuroendocrine carcinoma (NEC) has limited therapeutic options, with etoposide/cisplatin (EP) or etoposide/carboplatin (EC) remaining as the first-line standard. Serious adverse events occurred in 20.7% of pts in the ZG005+EP arms, with two cases (immune-mediated enterocolitis and subclinical myocarditis) deemed treatment-related. Conclusions The combination of ZG005 with standard EP based chemotherapy showed a favorable safety profile and encouraging anti-tumor activities in pts with NEC."

Clinical • Combination therapy • Metastases • Endocrine Cancer • Lung Cancer • Neuroendocrine Carcinoma • Oncology • Small Cell Lung Cancer • Solid Tumor • TIGIT

Durvalumab, carboplatin, and etoposide in patients who are treatment-naive with extensive-stage small-cell lung cancer and poor performance status (NEJ045A): a single-arm phase 2 trial. (PubMed, Lancet Respir Med) - "Durvalumab, carboplatin, and etoposide showed tolerability and promising efficacy as a first-line treatment for patients with untreated extensive-stage SCLC with poor performance status, supporting the integration of immune checkpoint inhibitors in this therapeutically challenging population."

Journal • P2 data • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

Final analysis of the Phase III GHSG HD21 trial: PET-guided brecadd vs. ebeacopp in advanced-stage classical Hodgkin lymphoma (ASH 2025) - P3 | "Introduction The German Hodgkin Study Group (GHSG) HD21 trial for adult patients with newly diagnosed advanced-stage classical Hodgkin lymphoma (AS-cHL) was designed to reduce treatment-related morbidity (TRMB)and improve efficacy by comparing the novel BrECADD regimen (brentuximab vedotin, etoposide,cyclophosphamide, doxorubicin, dacarbazine, dexamethasone) to the standard eBEACOPP protocol.Here, we report the final efficacy and safety including long-term progression-free survival (PFS), overallsurvival (OS), and late toxicity outcomes. While higher baseline lymphoma burden associates with incomplete remission atPET2, the risk for treatment failure seems mitigated through response-adaptation. Taken together, ourresults establish individualized BrECADD as a standard treatment option for adult patients with newlydiagnosed AS-cHL."

Metastases • P3 data • Acute Myelogenous Leukemia • Classical Hodgkin Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Lymphoma

Chemoradiation ± Atezolizumab in Limited-Stage Small Cell Lung Cancer: Results of NRG Oncology/Alliance LU005. (PubMed, J Clin Oncol) - P3 | "Concurrent and adjuvant atezolizumab with chemoradiation did not improve survival in patients with LS-SCLC."

Journal • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor

DAREON®-7: Phase I open-label dose-escalation/expansion study of first-line obrixtamig (BI 764532) plus platinum-doublet chemotherapy in patients with DLL3-positive neuroendocrine carcinomas (ENETS 2026) - P1 | "OBJECTIVES: We assessed the safety and efficacy of obrixtamig + carboplatin (or cisplatin) + etoposide in patients with DLL3-po - sitive NECs and report data from the ongoing dose-escalation/ expansion Phase I DAREON®-7 trial (NCT06132113). Obrixtamig with platinum + etoposide had a safety profile consistent with the individual treatments, supporting the tolerability of obrixtamig in combination regimens. Encouraging efficacy warrants the prioritized development of first-line obrixta - mig + platinum-doublet chemotherapy in these settings of high unmet need."

Clinical • P1 data • Endocrine Cancer • Hematological Disorders • Neuroendocrine Carcinoma • Oncology • Solid Tumor • DLL3

Primary vaginal yolk sac tumor in an 11-month-old girl: a case report. (PubMed, Front Oncol) - "She underwent hysteroscopic resection and six cycles of PEB (bleomycin, etoposide, cisplatin) chemotherapy. Primary vaginal yolk sac tumors are extremely rare and lack standardized treatment. Surgery combined with PEB chemotherapy proved effective in this case."

Journal • Gynecology • Oncology • Pediatrics

Dual-Biosensor for Five Drugs Detection in Precision Oncology. (PubMed, Bionanoscience) - "In this work, we propose a novel dual-biosensor platform for TDM, designed to simultaneously detect multiple chemotherapeutic agents-cyclophosphamide, ifosfamide, etoposide, methotrexate, and 5-fluorouracil-for precision oncology. By integrating MWCNTs with cytochrome P450 enzymes (CYP3A4 and CYP2B6), our platform achieves enhanced electron transfer and substrate specificity, enabling sensitive and selective detection of the five chemotherapeutic drugs, individually and in combination, within clinically relevant ranges. Designed for portability and rapid analysis, this dual-biosensor platform enables real-time, cost-effective drug monitoring at the point-of-care, advancing personalized cancer treatment with greater precision and accessibility."

Journal • Oncology • CYP3A4

Semen parameters in unirradiated, alkylating agent exposed childhood cancer survivors in the St. Jude Lifetime Cohort Study. (PubMed, Fertil Steril) - "Nearly half of those who received AA without radiation therapy experience oligospermia or azoospermia. CED, CiED, and treatment with etoposide are significantly associated with azoospermia and oligospermia. These results will inform pre-treatment counseling of patients and therapeutic study design."

Journal • Oncology

Solitary intracranial dural-based Ewing's sarcoma in a pregnant female: A case report. (PubMed, Radiol Case Rep) - "After the operation, the patient was treated with vincristine-doxorubicin-cyclophosphamide and ifosfamide-etoposide chemotherapy, which resulted in a partial radiological response. This case illustrates the diagnostic difficulties associated with intracranial ES due to its radiological similarity to meningioma and stresses the importance of immunohistochemical and genetic analysis for a conclusive diagnosis. Early multimodal management is vital for improving survival in such rare cases."

Journal • Brain Cancer • Ewing Sarcoma • Meningioma • Oncology • Pain • Sarcoma • Solid Tumor • CD99 • EWSR1

Acute oncology hospital care at home for post-chemotherapy monitoring. (PubMed, Support Care Cancer) - "Successful HaH admissions occurred for 92% of care episodes and provided significant hospital bed days saved. HaH demonstrated non-inferiority for healthcare utilization compared to standard inpatient monitoring, showcasing its potential to optimize resource utilization among this cohort of patients with MM receiving inpatient chemotherapy. These findings support the integration of HaH programs into oncology care and further studies are warranted to expand and refine HaH implementation in this population."

Journal • Retrospective data • Hematological Malignancies • Multiple Myeloma • Oncology

Synchronous Extensive-Stage Small Cell Lung Cancer and Multiple Myeloma Detected by Marked Hypergammaglobulinemia. (PubMed, Cureus) - "Dose-reduced carboplatin plus etoposide was initiated for SCLC with clinical improvement and no severe acute toxicity; treatment for myeloma was planned after stabilization of SCLC. This case highlights that extreme hypergammaglobulinemia in a patient with suspected lung cancer should trigger prompt evaluation for multiple myeloma. Dual malignancy can coexist and may be overlooked if clinicians focus on a single diagnosis."

Journal • Hematological Disorders • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Oncology • Pain • Pulmonary Disease • Respiratory Diseases • Small Cell Lung Cancer • Solid Tumor

Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia (clinicaltrials.gov) - P1/2 | N=51 | Completed | Sponsor: City of Hope Medical Center | Active, not recruiting ➔ Completed

Trial completion • Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology • Transplantation